Evolution of the Average Target: Cellectar Biosciences, Inc.

Evolution of the Average Target - Cellectar Biosciences, Inc.

Evolution of the Target Price: Cellectar Biosciences, Inc.

Evolution of the Target Price - Cellectar Biosciences, Inc.

Changes in Analyst Recommendations: Cellectar Biosciences, Inc.

23f1ef61bb3ef7f95d4cb5bb35a0d6cb.Xz6iy4txjDR5qq7BxrxvzmBHgFpy9VGJEAIyXIyXMiE.KA-aorJE40UT256Klu0i4wVz2TQKxyXxWU9EFe3ebWgad86i_xv5RRT87w~033ac759c0e77e6a8d21eb9559fd8ef7
27/10/25 Cellectar Says FDA Grants Rare Pediatric Drug Designation for Iopofosine in High-Grade Glioma MT
27/10/25 Cellectar Biosciences, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma CI
06/10/25 Cellectar wins EMA nod to seek conditional approval for iopofosine in rare blood cancer RE
06/10/25 Cellectar Biosciences Announces Iopofosine I 131 as A Treatment for Refractory (Post-Btki) Waldenstrom Macroglobulinemia (Wm) CI
19/11/24 Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $14, Maintains Outperform Rating MT
28/03/24 Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating MT
28/03/24 Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating MT
09/01/24 Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating MT
11/09/23 Oppenheimer Cuts Cellectar Biosciences Price Target to $8 From $10, Maintains Outperform Rating MT
05/05/23 Oppenheimer Adjusts Cellectar Biosciences Price Target to $10 From $11, Maintains Outperform Rating MT
04/11/22 HC Wainwright Adjusts Price Target on Cellectar Biosciences to $4 From $30, Maintains Buy Rating MT
04/11/22 Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating MT
08/08/22 Oppenheimer Adjusts Cellectar Biosciences Price Target to $47 From $5.50, Maintains Outperform Rating MT
02/02/22 Maxim Group Adjusts Cellectar Biosciences Price Target to $2 From $3, Maintains Buy Rating MT
28/12/20 Cellectar Biosciences : Oppenheimer Adjusts Cellectar Biosciences' Price Target to $5.50 From $5, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+1,199.14%
+6.21%
+2.74%
+10.45%
-1.39%
+17.23%
-1.28%
+20.12%
-1.83%
+4.11%
Average +125.55%
Weighted average by Cap. +6.21%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8829USD
Average target price
11.50USD
Spread / Average Target
+1,202.53%
High Price Target
15.00USD
Spread / Highest target
+1,598.95%
Low Price Target
10.00USD
Spread / Lowest Target
+1,032.63%

Analyst Consensus Detail

Analyst consensus - Cellectar Biosciences, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Cellectar Biosciences, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cellectar Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. CLRB Stock
  4. Consensus Cellectar Biosciences, Inc.